• OUTLOOK ARENA
  • VIEWS ON NEWS
  • MAY 25, 2002

Anxiety grips global markets

Gripped with anxiety and worries about terrorism, global markets remained depressed during the last week. US government’s admission that the bounce back in the economy may not be as strong as earlier anticipated added to the weakness.

The revised US GDP growth number for the first three months of the year at 5.6% was only marginally lower than its earlier estimates of 5.8% growth. This represents the strongest ever growth reported by the economy in the last two years. However, participants realized that there was devil in the details as the consumer and business spending failed to match expectations.

Europe’s biggest drug maker, GlaxoSmithkline (GSK) Plc shares hit a two year low on the last trading session after a US court quashed patents for its top selling anti-biotic, Augmentin, paving the way for generics. It was GSK’s second biggest selling drug last year with global annual sales of almost US$ 2 bn. However, the company is set to appeal against the ruling and would seek damages against generic players if it wins the case on appeal. Geneva, an affiliate of the Novartis is likely to be the first generic player to enter the market with the drug. However, Novartis AG shares also fell on Friday.

Meanwhile, Berkshire Hathaway Inc, created ripples by announcing a placement of the first ever negative interest rate securities, raising US$ 400m. These securities are convertible and investors showed willingness to accept a loss now, in the hopes of buying Berkshire shares at a good price five years down the line. The company only recently announced that a strong surge in demand for insurance and tightening of supply post Sept’11 resulted in insurance and re-insurance rates soaring, after a decade of decline. Berkshire declared a 51% rise in net profits for the quarter ended Mar’02. Earnings per share were US$ 598 (Rs 29,900) for the quarter. Berkshire's Class A stock, which has not been split in Buffett's 37 years at the company’s helm, trades at $75,700 (Rs 3.8 m a share).

Indian ADR’s: Roll coaster ride
(Price in $)18-May-0225-May-02Change
Dr. Reddy's21.321.92.8%
MTNL6.05.7-5.0%
Infosys67.063.3-5.5%
HDFC Bank15.315.1-1.3%
Wipro35.032.8-6.3%
Satyam10.810.90.9%
Rediff0.80.80.0%
VSNL7.77.6-1.3%
ICICI Bank7.16.8-4.2%
Satyam Infoway1.01.00.0%
Silverline1.71.70.0%

It was roll coaster ride last week. The week began with extreme pessimism over fears of war on the India-Pak border. Investors dumped stocks in the beginning of the week on signals of war. However, stock prices registered a smart recovery on the last trading session as war fears receded. Markets reacted positively to a tone down in aggressiveness from both India and Pakistan, emanating from several statements given by both sides yesterday.

With emerging pressure from countries across the globe, nerves seemed calming down. Moreover, the undertone of the PM's speech gave a feeling that the country was not interested in aggravating tensions unless the situation worsens. The derived interpretation of this could be that the military build up is more of a precautionary measure rather than a full-fledged war preparation. Markets seem to be re-considering the war risk premium. The bounce back in equities on the last trading day was not only in index heavyweights but also in the broader market.

Indian ADR’s moved inline with market sentiment. The highlight for the week was Satyam Computers, which remained heavily volatile during the week. Markets are expecting the company to divest its loss making subsidiary ‘Sify’ soon. Dr. Reddy’s ADR was the top gainer during the week. The company’s anti-diabetic molecule is in the last stage of clinical trials.

Red all around
Indices18-May-0225-May-02Change
Nikkei 11,847 11,976 1.1%
BSE 3,334 3,256 -2.3%
FTSE 5,218 5,169 -0.9%
Dow 10,353 10,104 -2.4%
Hang Seng 11,975 11,627 -2.9%
Dax 5,036 4,899 -2.7%
NASDAQ 1,741 1,661 -4.6%

Though slow, the expectation of recovery in the US is gaining ground. As far as India is concerned, the situation with Pakistan is likely to have a greater influence on the movement of the indices in the near term.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407